BBOT appoints Pedro Beltran as CEO, Idan Elmelech as COO, and Neil Kumar as Executive Chairman

BridgeBio Oncology Therapeutics, Inc.

Pedro Beltran, previously CSO, succeeds Eli Wallace as President and CEO effective April 20, 2026; also named Class III director.
Idan Elmelech, former SVP Strategy, promoted to COO, principal financial officer; Marc Cobo becomes principal accounting officer.
CFO Uneek Mehra departs April 30, 2026; no disagreement cited.
Neil Kumar appointed Executive Chairman; founder figure to guide next development phase.
Eli Wallace transitions to Senior Adviser; Board thanks him for service.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.